ORCID
0009-0000-6866-3431 (Seward)
Document Type
Article
Publication Date
2026
DOI
10.1016/j.jdcr.2025.11.031
Publication Title
JAAD Case Reports
Volume
70
Pages
19-21
Abstract
[Introduction] Crohn disease is a chronic inflammatory bowel disease that affects the gastrointestinal tract from the mouth to the anus. Extra-intestinal manifestations of Crohn disease are common, with the skin being the most commonly involved site.¹ Cutaneous manifestations of Crohn include lesions that directly extend from the bowel to the skin, whereas extraintestinal Crohn disease involves sites that do not directly extend from the bowel.¹ Extraintestinal Crohn disease is often resistant to treatments and often does not parallel the activity of the bowel disease.¹ There have only been 3 documented cases of extraintestinal Crohn disease responding to upadacitinib.²,³ We describe a patient with recalcitrant extraintestinal Crohn disease who responded well to upadacitinib allowing her to cease prior therapies.
Rights
© 2026 The Authors.
This is an open access article under the Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Original Publication Citation
Seward, A. H., & Callen, J. P. (2026). Upadacitinib for recalcitrant extraintestinal Crohn disease. JAAD Case Reports, 70, 19-21. https://doi.org/10.1016/j.jdcr.2025.11.031
Repository Citation
Seward, A. H., & Callen, J. P. (2026). Upadacitinib for recalcitrant extraintestinal Crohn disease. JAAD Case Reports, 70, 19-21. https://doi.org/10.1016/j.jdcr.2025.11.031